Research programme: transdermal carbohydrate macromolecules - Altea Therapeutics

Drug Profile

Research programme: transdermal carbohydrate macromolecules - Altea Therapeutics

Latest Information Update: 15 Nov 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer Altea Therapeutics
  • Class Carbohydrates
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Blood coagulation disorders

Most Recent Events

  • 12 Nov 2012 Nitto Denko acquires all assets of Altea Therapeutics
  • 09 Dec 2011 Discontinued - Preclinical for Coagulation disorders in USA (Transdermal)
  • 07 May 2007 Preclinical trials in Coagulation disorders in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top